Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, in…
Biotechnology
CN, Nanjing [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 0.00 | 2.10 | 2.10 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 12.14 | -2.53 | -2.88 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.00 | 2.78 | 2.78 | |
| Cash | 0.00 | 0.78 | 0.78 | |
| Capex | 0.00 | -0.09 | -0.09 | |
| Free Cash Flow | 0.00 | -0.05 | -0.05 | |
| Revenue | 0.00 | 0.62 | 0.62 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 0.75 | 0.75 | |
| Operating Margin | 0.00 | 0.11 | 0.11 | |
| ROA | 0.00 | -0.07 | -0.07 | |
| ROE | 0.00 | -0.11 | -0.11 | |
| ROIC | -0.92 | 0.02 | 0.02 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of 2096.HK is permitted for members.
5
Growth
The "Growth Entry" for the Focus of 2096.HK is permitted for members.
6
Leverage & Liquidity